Distinguishing Truncated and Normal MUC1 Glycoform Targeting from Tn-MUC1-Specific CAR T Cells: Specificity Is the Key to Safety

被引：20
|
作者：
Posey, Avery D., Jr. [1 ,2 ]
Clausen, Henrik [3 ,4 ]
June, Carl H. [1 ,2 ]
机构：
[1] Univ Penn, Ctr Cellular Immunotherapies, Philadelphia, PA 19104 USA
[2] Univ Penn, Parker Inst Canc Immunotherapy, Philadelphia, PA 19104 USA
[3] Univ Copenhagen, Fac Hlth Sci, Copenhagen Ctr Glyc, Dept Cellular & Mol Med, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark
[4] Univ Copenhagen, Fac Hlth Sci, Copenhagen Ctr Glyc, Dept Odontol, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark
来源：
IMMUNITY | 2016年 / 45卷 / 05期
关键词：
CHIMERIC ANTIGEN RECEPTOR; PROTEIN;
D O I：
10.1016/j.immuni.2016.10.015
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：947 / 948
页数：2
相关论文
共 50 条
  • [1] MUC1*targeting CAR T
    Bamdad, Cynthia Carol
    Stewart, Andrew K.
    Smagghe, Benoit J.
    Deary, Luke T.
    Kohler, Victoria L.
    Dietz, Jared L.
    CANCER RESEARCH, 2017, 77
  • [2] Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma
    Posey, Avery D., Jr.
    Schwab, Robert D.
    Boesteanu, Alina C.
    Steentoft, Catharina
    Mandel, Ulla
    Engels, Boris
    Stone, Jennifer D.
    Madsen, Thomas D.
    Schreiber, Karin
    Haines, Kathleen M.
    Cogdill, Alexandria P.
    Chen, Taylor J.
    Song, Decheng
    Scholler, John
    Kranz, David M.
    Feldman, Michael D.
    Young, Regina
    Keith, Brian
    Schreiber, Hans
    Clausen, Henrik
    Johnson, Laura A.
    June, Carl H.
    IMMUNITY, 2016, 44 (06) : 1444 - 1454
  • [3] Targeting of Tumor-Associated Glycoforms of MUC1 with CAR T Cells
    Maher, John
    Wilkie, Scott
    Davies, David M.
    Arif, Sefina
    Picco, Gianfranco
    Julien, Sylvain
    Foster, Julie
    Burchell, Joy
    Taylor-Papadimitriou, Joyce
    IMMUNITY, 2016, 45 (05) : 945 - 946
  • [4] CAR T cells that target full-length MUC1 enrich for MUC1*and induce metastasis
    Bamdad, Cynthia C.
    Stewart, Andrew K.
    Deary, Luke T.
    Smagghe, Benoit J.
    Huang, Pengyu
    Glennie, Nelson D.
    Swanson, Tyler E.
    CANCER RESEARCH, 2018, 78 (13)
  • [5] Expression of MUC1 mucin on activated human T cells: Implications for a role of MUC1 in normal immune regulation
    Agrawal, B
    Krantz, MJ
    Parker, J
    Longenecker, BM
    CANCER RESEARCH, 1998, 58 (18) : 4079 - 4081
  • [6] Differential expression of MUC1 on transfected cell lines influences its recognition by MUC1 specific T cells
    MagarianBlander, J
    Hughey, RP
    Kinlough, C
    Poland, PA
    Finn, OJ
    GLYCOCONJUGATE JOURNAL, 1996, 13 (05) : 749 - 756
  • [7] Phase I/II Trial of MUC1*-CAR-1XX T Cells
    Bamdad, Cynthia
    Mortimer, Joanne
    Yuan, Yuan
    Specht, Jennifer
    Stewart, Andrew
    Smagghe, Benoit
    Lin, Stephen
    Carter, Mark
    Synold, Tim
    Parekh, Vishwas
    Walkley, Danica
    Budde, Lihua E.
    Liu-Michael, Qing
    Yi, Kevin
    Nash, Jac-Leen
    Nash, Michael
    Marquez, Jacy
    Kim, Teresa
    Hamilton, Stan
    Forman, Stephen J.
    MOLECULAR THERAPY, 2023, 31 (04) : 397 - 397
  • [8] Phase I study of adoptive immunotherapy for advanced MUC1*positive breast cancer with autologous T cells engineered to express a chimeric antigen receptor, huMNC2-CAR44 specific for a cleaved form of MUC1 (MUC1*).
    Specht, Jennifer M.
    Maloney, David G.
    Yeung, Cecilia
    Wu, Vicky
    Bamdad, Cynthia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] Phase I/II first-in-human CAR T-targeting MUC1 transmembrane cleavage product (MUC1*) in patients with metastatic breast cancer
    Bamdad, Cynthia Carol
    Yuan, Yuan
    Specht, Jennifer M.
    Stewart, Andrew K.
    Smagghe, Benoit J.
    Lin, Stephen Chi-Min
    Carter, Mark G.
    Synold, Timothy W.
    Frankel, Paul Henry
    Parekh, Vishwas
    Walkley, Danica M.
    Budde, L. Elizabeth
    Liu-Michael, Qing
    Nash, Jac-Leen
    Nash, Michael J.
    Reale, Laura M.
    Yi, Kevin Y.
    Kim, Teresa
    Hamilton, Stanley R.
    Forman, Stephen J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] Phase I study of adoptive immunotherapy for advanced MUC1*positive breast cancer with autologous T cells engineered to express a chimeric antigen receptor, huMNC2-CAR44 specific for a cleaved form of MUC1 (MUC1*)
    Specht, Jennifer Marie
    Maloney, David
    Yeung, Cecilia
    Wu, Qian
    Bamdad, Cynthia
    CANCER RESEARCH, 2021, 81 (04)
12345